FBLG FIBROBIOLOGICS INC.

FibroBiologics Announces 2025 Annual Meeting of Stockholders

FibroBiologics Announces 2025 Annual Meeting of Stockholders

HOUSTON, March 27, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that its 2025 Annual Meeting of Stockholders will take place on June 12, 2025, at 11 a.m. CDT, exclusively through a virtual format. The record date for determination of stockholders entitled to vote at the annual meeting is April 14, 2025.

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit .

General Inquiries:

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697



EN
27/03/2025

Underlying

FBLGFIBROBIOLOGICS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIBROBIOLOGICS INC.

 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics to Present at the Advanced Wound Care Summit USA

FibroBiologics to Present at the Advanced Wound Care Summit USA HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research a...

July 11, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenera...

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank HOUSTON, July 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced an advancement in its cartilage repair program. FibroBiologics has confirmed, through both immunohistochem...

July 9, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A ...

FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 HOUSTON, July 07, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, is pleased to invite investors to a webinar on July 10, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature FibroBiologics’ Founder and Chief Executive Off...

July 7, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financin...

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has closed the third $5 million tranche of the previously announced Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”), an investment fund managed by Yorkvill...

June 16, 2025 1 EN
 PRESS RELEASE
Free
FBLG FIBROBIOLOGICS ...

FibroBiologics to Present at the BIO International Convention 2025

FibroBiologics to Present at the BIO International Convention 2025 HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include rece...

June 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch